{
    "2019-02-25": [
        [
            {
                "time": "",
                "original_text": "长春高新欲打破“骨干”子公司治理僵局 核心高管去留仍无定论",
                "features": {
                    "keywords": [
                        "长春高新",
                        "子公司",
                        "治理僵局",
                        "核心高管"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【天风医药】一周医讯：继续看好后续医药板块行情，关注业绩高增长标的",
                "features": {
                    "keywords": [
                        "天风医药",
                        "医药板块",
                        "行情",
                        "业绩高增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业跨市场周报:带量采购愈推进, CRO创新主线愈受益",
                "features": {
                    "keywords": [
                        "医药生物",
                        "带量采购",
                        "CRO",
                        "创新主线"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业:两会政策决定医药产业走势, 政策免疫板块仍是首选",
                "features": {
                    "keywords": [
                        "医药生物",
                        "两会政策",
                        "政策免疫",
                        "板块首选"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "长春高新:拟重组金赛30%股权,有望提升公司核心价值",
                "features": {
                    "keywords": [
                        "长春高新",
                        "重组",
                        "金赛",
                        "核心价值"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}